Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer

Andrew Graham Hill, Michael Findlay, Matthew Burge, Christopher Jackson, Pilar Garcia Alfonso, Leslie Samuel, Vinod Ganju, Meinolf Karthaus, Alessio Amatu, Mark Jeffrey, Maria Di Bartolomeo, John Bridgewater, Andrew Coveler, Manuel Hidalgo, Amy Kapp, Roxanna Sufan, Bruce McCall, William Hanley, Elicia Penuel, Andrea PirzkallJosep Tabernero

Research output: Contribution to journalArticle

9 Citations (Scopus)
6 Downloads (Pure)

Fingerprint Dive into the research topics of 'Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in <i>RAS</i> wild-type metastatic colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences